Characterization of novel therapeutic targets in chronic myeloid leukemia
The identification of BCR-ABL1 as the key molecular event in chronic myeloid leukemia (CML) has revolutionized treatment opportunities for early phase patients. Imatinib mesylate (IM) and other ABL1 tyrosine kinase inhibitors (TKIs) have been introduced into the clinic with remarkable effects. Howev...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2016
|
| Online Access: | http://hdl.handle.net/2429/56175 |